Published in Postgrad Med J on May 01, 2003
Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation. Neuron (2015) 2.09
The Saudi Initiative for Asthma. Ann Thorac Med (2009) 1.31
Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics. Thorax (2006) 1.01
Similarities and differences between asthma health care professional and patient views regarding medication adherence. Can Respir J (2014) 0.82
Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. BMC Pulm Med (2013) 0.79
Management of paediatric asthma. Postgrad Med J (2004) 0.78
Patient-centered care and its effect on outcomes in the treatment of asthma. Patient Relat Outcome Meas (2011) 0.75
Inhaled corticosteroids improve lung function, airway hyper-responsiveness and airway inflammation but not symptom control in patients with mild intermittent asthma: A meta-analysis. Exp Ther Med (2017) 0.75
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (2002) 8.57
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med (2002) 6.52
British guideline on the management of asthma. Thorax (2003) 5.86
Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med (2001) 5.47
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 5.25
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet (1994) 4.77
Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med (1991) 4.09
Qualitative study of views of health professionals and patients on guided self management plans for asthma. BMJ (2000) 3.78
Non-eosinophilic corticosteroid unresponsive asthma. Lancet (1999) 3.25
Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med (2000) 3.24
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol (2001) 3.19
The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med (2000) 3.08
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med (1990) 2.80
Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet (1997) 2.80
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet (1995) 2.79
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J (2001) 2.77
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol (2000) 2.51
Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev (2000) 2.47
Inhaled steroids and the risk of hospitalization for asthma. JAMA (1997) 2.45
The costs of asthma. Eur Respir J (1996) 2.44
Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax (1990) 2.43
Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. Eur Respir J (2000) 2.42
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet (1999) 2.37
Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med (1992) 2.32
Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet (1991) 2.27
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med (1994) 2.11
A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med (1992) 2.10
Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax (2002) 2.08
Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med (1994) 2.02
Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin Invest (1998) 1.94
Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther (1999) 1.93
A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants. Arch Pediatr Adolesc Med (2000) 1.85
A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med (1997) 1.84
Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax (1991) 1.79
Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis (1992) 1.75
Inhaled and oral salbutamol in exercise-induced asthma. Am Rev Respir Dis (1976) 1.72
Prednisone-dependent asthma: inflammatory indices in induced sputum. Eur Respir J (1999) 1.68
Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. Am J Respir Crit Care Med (1996) 1.64
Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med (1999) 1.62
Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet (1994) 1.61
Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ (2001) 1.61
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest (2001) 1.59
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest (2001) 1.57
The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy (1999) 1.52
Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol (2001) 1.52
Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 1.52
Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J (1999) 1.48
A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol (1994) 1.47
Validity of peak expiratory flow rate variability for the diagnosis of asthma. Clin Sci (Lond) (1993) 1.44
Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax (1997) 1.43
Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy (1998) 1.39
A comparison of the validity of different diagnostic tests in adults with asthma. Chest (2002) 1.36
Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J (1996) 1.33
Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol (2001) 1.32
Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. Thorax (2003) 1.29
Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med (1994) 1.28
Beta-adrenergic bronchodilators. N Engl J Med (1995) 1.27
Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J (1997) 1.26
Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial. Lancet (2001) 1.24
Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol (1998) 1.24
A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest (1993) 1.23
Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax (1999) 1.21
Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. J Allergy Clin Immunol (1984) 1.20
Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med (2000) 1.20
Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax (2000) 1.20
Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax (1995) 1.19
Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis (1992) 1.18
Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J (1998) 1.16
A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest (2000) 1.12
Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. J Allergy Clin Immunol (1998) 1.08
Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ (2002) 1.04
Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax (2000) 1.04
A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis (1991) 1.00
Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. Am J Med (2000) 0.96
Cigarette smoking and asthma. Monaldi Arch Chest Dis (2001) 0.96
The long-term effects of nedocromil sodium and beclomethasone dipropionate on bronchial responsiveness to methacholine in nonatopic asthmatic subjects. Am Rev Respir Dis (1990) 0.95
Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J (1995) 0.92
Easy bruising as a side-effect of inhaled corticosteroids. Eur Respir J (1992) 0.92
Inhaled short acting beta2-agonist use in asthma: regular vs as needed treatment. Cochrane Database Syst Rev (2000) 0.86
Sodium cromoglycate (Intal) as an anti-inflammatory agent for the treatment of chronic asthma. Clin Exp Allergy (1994) 0.85
Allergen immunotherapy for asthma. Cochrane Database Syst Rev (2000) 0.84
Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial. Can Respir J (1998) 0.83
Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma. J Asthma (1997) 0.82
Salmeterol versus theophylline in the treatment of asthma. Ann Allergy Asthma Immunol (1997) 0.81
A placebo-controlled multicenter study of auranofin in the treatment of patients with corticosteroid-dependent asthma. Auranofin Multicenter Drug Trial. J Allergy Clin Immunol (1996) 0.81
A cost analysis on the pattern of asthma prescribing in the UK. Eur Respir J (1999) 0.80
Influence of natural antigenic exposure on expiratory flows, methacholine responsiveness, and airway inflammation in mild allergic asthma. J Allergy Clin Immunol (1993) 0.80
House dust mite control measures for asthma. Cochrane Database Syst Rev (2001) 0.79
Management of steroid-dependent asthma with methotrexate: a meta-analysis of randomized clinical trials. Respir Med (1998) 0.79
Long acting beta-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev (2000) 0.79
Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev (2000) 0.78
Physical training for asthma. Cochrane Database Syst Rev (2000) 0.78
Alternative agents for anti-inflammatory treatment of asthma. J Allergy Clin Immunol (1998) 0.77
Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest (1991) 3.88
The use of induced sputum to investigate airway inflammation. Thorax (1997) 3.85
Eosinophilic bronchitis is an important cause of chronic cough. Am J Respir Crit Care Med (1999) 3.84
Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis (1990) 3.70
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000) 3.63
Non-eosinophilic corticosteroid unresponsive asthma. Lancet (1999) 3.25
A new perspective on concepts of asthma severity and control. Eur Respir J (2008) 3.16
Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis (1989) 3.06
Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax (2003) 2.93
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J (2007) 2.78
Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ (1993) 2.70
Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax (2002) 2.63
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet (1990) 2.52
CCR7 expression and memory T cell diversity in humans. J Immunol (2001) 2.42
Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med (1995) 2.25
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol (2012) 2.17
Respiratory medicine: fighting for survival. BMJ (1992) 2.15
The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J (2008) 2.01
Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD. Respiration (2009) 1.92
IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology (1990) 1.85
Airway inflammation, airway responsiveness and cough before and after inhaled budesonide in patients with eosinophilic bronchitis. Eur Respir J (2000) 1.81
Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax (2005) 1.81
Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration (2011) 1.78
Multi-dimensional phenotyping: towards a new taxonomy for airway disease. Clin Exp Allergy (2005) 1.77
Comparison of airway immunopathology of eosinophilic bronchitis and asthma. Thorax (2003) 1.75
Activation of human lung mast cells by monomeric immunoglobulin E. Eur Respir J (2005) 1.74
Human eosinophil, but not neutrophil, adherence to IL-1-stimulated human umbilical vascular endothelial cells is alpha 4 beta 1 (very late antigen-4) dependent. J Immunol (1991) 1.67
Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol (2001) 1.67
Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med (1991) 1.64
New insights into the role of the mast cell in asthma. Clin Exp Allergy (2003) 1.61
Interleukin-5 selectively enhances the chemotactic response of eosinophils obtained from normal but not eosinophilic subjects. Blood (1992) 1.59
The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin Exp Allergy (2005) 1.52
Expression of CCR8 is increased in asthma. Clin Exp Allergy (2010) 1.51
Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. Thorax (2003) 1.51
New insights into the relationship between airway inflammation and asthma. Clin Sci (Lond) (2002) 1.47
Leukotriene antagonists and symptom control in chronic persistent asthma. Lancet (2001) 1.46
Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. Eur Respir J (2006) 1.45
Functional KCa3.1 K+ channels are required for human lung mast cell migration. Thorax (2006) 1.39
Interleukin-4 and -13 expression is co-localized to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy (2003) 1.37
Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med (2001) 1.31
Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur Respir J (2007) 1.30
Genome-wide association study to identify genetic determinants of severe asthma. Thorax (2012) 1.27
Adhesion to fibronectin prolongs eosinophil survival. J Exp Med (1993) 1.25
Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism. J Leukoc Biol (2000) 1.24
Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med (1999) 1.24
Transfection of cells from patients with leukocyte adhesion deficiency with an integrin beta subunit (CD18) restores lymphocyte function-associated antigen-1 expression and function. J Clin Invest (1990) 1.24
Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin Exp Allergy (2005) 1.22
Idiopathic chronic cough: association with organ specific autoimmune disease and bronchoalveolar lymphocytosis. Thorax (2003) 1.19
Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent. J Exp Med (1994) 1.17
Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma. Am J Respir Crit Care Med (2000) 1.15
Expression of endothelial and leukocyte adhesion molecules interacellular adhesion molecule-1, E-selectin, and vascular cell adhesion molecule-1 in the bronchial mucosa in steady-state and allergen-induced asthma. J Allergy Clin Immunol (1993) 1.14
Granulocyte-macrophage colony-stimulating factor expression in induced sputum and bronchial mucosa in asthma and COPD. Thorax (2009) 1.14
Asthma control during and after cessation of regular beta 2-agonist treatment. Am Rev Respir Dis (1993) 1.13
Inflammatory cell microlocalisation and airway dysfunction: cause and effect? Eur Respir J (2007) 1.11
Effects of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy (1988) 1.07
Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow. Blood (2000) 1.07
Structure and regulation of the leukocyte adhesion receptor LFA-1 and its counterreceptors, ICAM-1 and ICAM-2. Cold Spring Harb Symp Quant Biol (1989) 1.07
Is the neutrophil the key effector cell in severe asthma? Thorax (2005) 1.06
Adenosine monophosphate and histamine induced bronchoconstriction: repeatability and protection by terbutaline. Thorax (1997) 1.02
Mast cells express IL-13R alpha 1: IL-13 promotes human lung mast cell proliferation and Fc epsilon RI expression. Allergy (2006) 1.02
Observational study of the natural history of eosinophilic bronchitis. Clin Exp Allergy (2005) 1.01
Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics. Thorax (2006) 1.01
Chemokines and their receptors as potential targets for the treatment of asthma. Br J Pharmacol (2007) 1.01
A case of cough, lymphocytic bronchoalveolitis and coeliac disease with improvement following a gluten free diet. Thorax (2002) 1.00
Sputum induction to assess airway inflammation: is it an inflammatory stimulus? Thorax (1998) 1.00
Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur Respir J (2005) 0.99
IFN-gamma induces expression of Fc gamma RIII (CD16) on human eosinophils. J Immunol (1992) 0.99
Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspases in human eosinophils. Blood (2001) 0.98
CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology (1993) 0.98
Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants. Thorax (2002) 0.97